ClinicalTrials.gg
CompletedNCT03936777Updated Nov 17, 2025Results posted

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

A Phase 3 interventional study of ZX008 (Fenfluramine Hydrochloride) in Dravet Syndrome, Lennox Gastaut Syndrome and Epileptic Encephalopathy, sponsored by Zogenix, Inc.. Completed at 71 sites in 14 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
412
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing fenfluramine in Epilepsies, Myoclonic — 2 open to participants now, 2 under way, none of them phase 3. Fenfluramine · Epilepsies, Myoclonic.

Enrollment
Largest of 11
412 · median 25
Started
2019
the only one that year
Phase 3
7 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Zogenix, Inc.

Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, this one has the largest enrollment, is the only one that started in 2019, is one of 7 in phase 3, and was the 6th registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

2 of the 11 studies testing fenfluramine in Epilepsies, Myoclonic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fenfluramine

Fenfluramine: first FDA approval 2020 (FINTEPLA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing fenfluramine in Epilepsies, Myoclonic, or all of them as a file.
02

Study summary

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy

Read the detailed description

This is an international, multicenter, open-label, long-term safety study of ZX008 in patients with epileptic encephalopathy, including Dravet syndrome or Lennox-Gastaut syndrome. Subjects eligible for participation are those with Dravet syndrome who are currently enrolled in Study ZX008-1503, or those with Lennox-Gastaut syndrome who have successfully completed Study ZX008-1601-Part 2, and are candidates for continued treatment with ZX008 for an extended period of time, or those with Dravet syndrome, Lennox-Gastaut syndrome, or another epileptic encephalopathy who have completed participation in another Zogenix-sponsored study and have been invited to participate in this study.

03

Conditions studied

  • Dravet Syndrome
  • Lennox Gastaut Syndrome
  • Epileptic Encephalopathy
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or nonpregnant, nonlactating female
  • Satisfactory completion of a core study
  • Has a rare seizure disorder, such as epileptic encephalopathy and has successfully completed another Zogenix-sponsored clinical trials with ZX008
  • Subject's caregiver is willing and able to be compliant with study procedures, visit schedule and study drug accountability

Exclusion criteria

Exclusion Criteria:

  • Current cardiac valvulopathy or pulmonary hypertension that is
  • Moderate or severe hepatic impairment
  • Receiving monoamine oxidase inhibitors, serotonin agonists, serotonin antagonists, and serotonin reuptake inhibitors within 14 days of receiving ZX008
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
412 participants (actual)

Study arms

  • Experimental
    ZX008 (Fenfluramine Hydrochloride)

    ZX008 is supplied as an open-label oral solution.Doses will include up to 0.8 mg/kg/day divided into 2 daily doses, up to a maximum of 30 mg/day (subjects taking concomitant STP will receive up to 0.5 mg/kg/day, up to a maximum of 20 mg/day) in a concentration of 2.5 mg/mL.

    Drug: ZX008 (Fenfluramine Hydrochloride)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs were defined as AE that began on or after the first day of treatment with ZX008 in Study EP0215 (ZX008-1900) (NCT03936777) or that occurred prior to first ZX008 treatment in Study EP0215 (ZX008-1900) but increased in severity after treatment in Study EP0215 (ZX008-1900) began. Events recorded at Follow-up/Cardiac Follow-up were considered treatment-emergent. The percentage of participants was rounded to one decimal place.

    Time frame: From First dose of ZX008 (in study EP0215 [ZX008-1900]) to Cardiac Follow-up after ZX008 treatment (Up to 6 Years, 17 Days)

Secondary outcomes

  1. Clinical Global Impression-Improvement in Participants, Subscale Global: Assessment by Parent/Caregiver

    The Clinical Global Impression-Improvement (CGI-I) scale is used to assess the severity of illness and global improvement in patients. Global function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The global CGI-I assessment was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

    Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)

  2. Clinical Global Impression-Improvement in Participants, Subscale Global: Assessment by Investigator

    The CGI-I scale is used to assess the severity of illness and global improvement in patients. Global function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The global CGI-I assessment was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

    Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)

  3. Clinical Global Impression-Improvement in Participants, Subscale Cognition: Assessment by Parent/Caregiver

    The CGI-I scale is used to assess the severity of illness and global improvement in patients. Cognitive function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of cognition was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

    Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)

  4. Clinical Global Impression-Improvement in Participants, Subscale Behavior: Assessment by Parent/Caregiver

    The CGI-I scale is used to assess the severity of illness and global improvement in patients. Behavior is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of behavior was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

    Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)

  5. Clinical Global Impression-Improvement in Participants, Subscale Motor Abilities: Assessment by Parent/Caregiver

    The CGI-I scale is used to assess the severity of illness and global improvement in patients. Motor abilities function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of motor abilities was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

    Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)

  6. Clinical Global Impression-Improvement in Participants, Subscale Cognition: Assessment by Investigator

    The CGI-I scale is used to assess the severity of illness and global improvement in patients. Cognitive function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of cognition was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

    Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)

  7. Clinical Global Impression-Improvement in Participants, Subscale Behavior: Assessment by Investigator

    The CGI-I scale is used to assess the severity of illness and global improvement in patients. Behavior is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of behavior was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

    Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)

  8. Clinical Global Impression Improvement in Participants, Subscale Motor Abilities: Assessment by Investigator

    The CGI-I scale is used to assess the severity of illness and global improvement in patients. Motor abilities is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of motor abilities was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

    Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)

  9. Number of Participants With Improvement in Seizure Burden as Assessed by the Investigator

    The change in seizure burden from the previous visit was assessed by the investigator using following categories: \<25%, ≥25%, ≥50%, ≥75%, 100% (i.e., seizure-free) improvement. Improvement in seizure burden at Baseline was based on comparison with the participant's last visit in the feeder studies (ZX008-1601, ZX008-1503, and ZX008-1602). Number of participants in each of the 5 categories is reported for each visit as compared to last visit.

    Time frame: Baseline (Day 1), Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)

07

Results

Posted Nov 17, 2025

Participant flow

The study started to enroll participants in April 2019 and concluded in May 2025.

Participant flow — Overall Study
MilestoneAny ZX008 Open Label Dose
Started412
Completed360
Not completed52
Withdrew: Adverse event3
Withdrew: Death3
Withdrew: Lack of efficacy24
Withdrew: Lost to follow-up3
Withdrew: Physician decision1
Withdrew: Withdrawal by subject11
Withdrew: Subjected weaned of zx0081
Withdrew: Missing6

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs were defined as AE that began on or after the first day of treatment with ZX008 in Study EP0215 (ZX008-1900) (NCT03936777) or that occurred prior to first ZX008 treatment in Study EP0215 (ZX008-1900) but increased in severity after treatment in Study EP0215 (ZX008-1900) began. Events recorded at Follow-up/Cardiac Follow-up were considered treatment-emergent. The percentage of participants was rounded to one decimal place.

Time frame:
From First dose of ZX008 (in study EP0215 [ZX008-1900]) to Cardiac Follow-up after ZX008 treatment (Up to 6 Years, 17 Days)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsAny ZX008 Open Label Dose
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)75.5
SecondaryClinical Global Impression-Improvement in Participants, Subscale Global: Assessment by Parent/Caregiver

The Clinical Global Impression-Improvement (CGI-I) scale is used to assess the severity of illness and global improvement in patients. Global function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The global CGI-I assessment was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

Time frame:
Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Reported as:
Count of participants · Participants
Clinical Global Impression-Improvement in Participants, Subscale Global: Assessment by Parent/Caregiver
ParticipantsAny ZX008 Open Label Dose
Month 6: Very much improved39
Month 6: Much improved88
Month 6: Minimally improved87
Month 6: No change124
Month 6: Minimally worse23
Month 6: Much worse7
Month 6: Very much worse3
Month 12: Very much improved42
Month 12: Much improved65
Month 12: Minimally improved56
Month 12: No change77
Month 12: Minimally worse17
Month 12: Much worse9
Month 12: Very much worse0
Month 18: Very much improved34
Month 18: Much improved43
Month 18: Minimally improved60
Month 18: No change67
Month 18: Minimally worse16
Month 18: Much worse2
Month 18: Very much worse1
Month 24: Very much improved33
Month 24: Much improved46
Month 24: Minimally improved41
Month 24: No change59
Month 24: Minimally worse8
Month 24: Much worse1
Month 24: Very much worse0
Month 30: Very much improved16
Month 30: Much improved41
Month 30: Minimally improved34
Month 30: No change47
Month 30: Minimally worse9
Month 30: Much worse1
Month 30: Very much worse1
Month 36: Very much improved16
Month 36: Much improved31
Month 36: Minimally improved29
Month 36: No change39
Month 36: Minimally worse10
Month 36: Much worse3
Month 36: Very much worse0
Last On-Treatment Visit: Very much improved71
Last On-Treatment Visit: Much improved109
Last On-Treatment Visit: Minimally improved85
Last On-Treatment Visit: No change108
Last On-Treatment Visit: Minimally worse21
Last On-Treatment Visit: Much worse7
Last On-Treatment Visit: Very much worse0
SecondaryClinical Global Impression-Improvement in Participants, Subscale Global: Assessment by Investigator

The CGI-I scale is used to assess the severity of illness and global improvement in patients. Global function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The global CGI-I assessment was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

Time frame:
Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Reported as:
Count of participants · Participants
Clinical Global Impression-Improvement in Participants, Subscale Global: Assessment by Investigator
ParticipantsAny ZX008 Open Label Dose
Month 6: Very much improved23
Month 6: Much improved86
Month 6: Minimally improved85
Month 6: No change141
Month 6: Minimally worse26
Month 6: Much worse4
Month 6: Very much worse2
Month 12: Very much improved28
Month 12: Much improved63
Month 12: Minimally improved66
Month 12: No change87
Month 12: Minimally worse17
Month 12: Much worse3
Month 12: Very much worse1
Month 18: Very much improved23
Month 18: Much improved45
Month 18: Minimally improved58
Month 18: No change86
Month 18: Minimally worse12
Month 18: Much worse1
Month 18: Very much worse0
Month 24: Very much improved20
Month 24: Much improved54
Month 24: Minimally improved37
Month 24: No change72
Month 24: Minimally worse5
Month 24: Much worse1
Month 24: Very much worse0
Month 30: Very much improved11
Month 30: Much improved44
Month 30: Minimally improved34
Month 30: No change56
Month 30: Minimally worse3
Month 30: Much worse1
Month 30: Very much worse0
Month 36: Very much improved7
Month 36: Much improved33
Month 36: Minimally improved25
Month 36: No change52
Month 36: Minimally worse5
Month 36: Much worse2
Month 36: Very much worse0
Last On-Treatment Visit: Very much improved33
Last On-Treatment Visit: Much improved108
Last On-Treatment Visit: Minimally improved101
Last On-Treatment Visit: No change134
Last On-Treatment Visit: Minimally worse19
Last On-Treatment Visit: Much worse5
Last On-Treatment Visit: Very much worse1
SecondaryClinical Global Impression-Improvement in Participants, Subscale Cognition: Assessment by Parent/Caregiver

The CGI-I scale is used to assess the severity of illness and global improvement in patients. Cognitive function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of cognition was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

Time frame:
Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Reported as:
Count of participants · Participants
Clinical Global Impression-Improvement in Participants, Subscale Cognition: Assessment by Parent/Caregiver
ParticipantsAny ZX008 Open Label Dose
Month 6: Very much improved26 (4.6 to 10.1)
Month 6: Much improved75 (16.3 to 24.7)
Month 6: Minimally improved87 (19.3 to 28.2)
Month 6: No change161 (38.4 to 48.7)
Month 6: Minimally worse15 (2.3 to 6.6)
Month 6: Much worse4 (0.3 to 2.7)
Month 6: Very much worse2 (0.1 to 1.9)
Month 12: Very much improved17 (3.8 to 10.1)
Month 12: Much improved54 (15.7 to 25.7)
Month 12: Minimally improved78 (24.0 to 35.3)
Month 12: No change108 (34.8 to 46.9)
Month 12: Minimally worse5 (0.6 to 4.3)
Month 12: Much worse3 (0.2 to 3.3)
Month 12: Very much worse0 (0 to 1.4)
Month 18: Very much improved18 (4.8 to 12.4)
Month 18: Much improved43 (14.3 to 25.0)
Month 18: Minimally improved69 (24.8 to 37.3)
Month 18: No change86 (32.0 to 45.1)
Month 18: Minimally worse6 (1.0 to 5.7)
Month 18: Much worse2 (0.1 to 3.2)
Month 18: Very much worse0 (0 to 1.6)
Month 24: Very much improved14 (4.1 to 12.2)
Month 24: Much improved35 (13.3 to 24.9)
Month 24: Minimally improved59 (24.8 to 38.5)
Month 24: No change73 (31.8 to 46.2)
Month 24: Minimally worse6 (1.2 to 6.8)
Month 24: Much worse1 (0.0 to 2.9)
Month 24: Very much worse0 (0 to 1.9)
Month 30: Very much improved7 (1.9 to 9.4)
Month 30: Much improved31 (14.6 to 28.2)
Month 30: Minimally improved41 (20.5 to 35.4)
Month 30: No change62 (33.6 to 50.0)
Month 30: Minimally worse6 (1.5 to 8.6)
Month 30: Much worse1 (0.0 to 3.7)
Month 30: Very much worse1 (0.0 to 3.7)
Month 36: Very much improved6 (1.7 to 9.9)
Month 36: Much improved32 (17.8 to 33.4)
Month 36: Minimally improved29 (15.7 to 30.9)
Month 36: No change49 (29.8 to 47.3)
Month 36: Minimally worse11 (4.4 to 14.9)
Month 36: Much worse1 (0.0 to 4.3)
Month 36: Very much worse0 (0 to 2.8)
Last On-Treatment Visit: Very much improved33 (5.7 to 11.4)
Last On-Treatment Visit: Much improved98 (20.3 to 28.9)
Last On-Treatment Visit: Minimally improved101 (21.0 to 29.7)
Last On-Treatment Visit: No change148 (32.2 to 41.8)
Last On-Treatment Visit: Minimally worse16 (2.3 to 6.4)
Last On-Treatment Visit: Much worse5 (0.4 to 2.9)
Last On-Treatment Visit: Very much worse0 (0 to 0.9)
SecondaryClinical Global Impression-Improvement in Participants, Subscale Behavior: Assessment by Parent/Caregiver

The CGI-I scale is used to assess the severity of illness and global improvement in patients. Behavior is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of behavior was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

Time frame:
Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Reported as:
Count of participants · Participants
Clinical Global Impression-Improvement in Participants, Subscale Behavior: Assessment by Parent/Caregiver
ParticipantsAny ZX008 Open Label Dose
Month 6: Very much improved20
Month 6: Much improved51
Month 6: Minimally improved75
Month 6: No change174
Month 6: Minimally worse35
Month 6: Much worse12
Month 6: Very much worse3
Month 12: Very much improved9
Month 12: Much improved46
Month 12: Minimally improved51
Month 12: No change120
Month 12: Minimally worse28
Month 12: Much worse11
Month 12: Very much worse0
Month 18: Very much improved13
Month 18: Much improved37
Month 18: Minimally improved42
Month 18: No change100
Month 18: Minimally worse27
Month 18: Much worse4
Month 18: Very much worse1
Month 24: Very much improved13
Month 24: Much improved31
Month 24: Minimally improved36
Month 24: No change83
Month 24: Minimally worse16
Month 24: Much worse9
Month 24: Very much worse0
Month 30: Very much improved8
Month 30: Much improved26
Month 30: Minimally improved27
Month 30: No change69
Month 30: Minimally worse15
Month 30: Much worse4
Month 30: Very much worse0
Month 36: Very much improved7
Month 36: Much improved18
Month 36: Minimally improved28
Month 36: No change58
Month 36: Minimally worse10
Month 36: Much worse6
Month 36: Very much worse1
Last On-Treatment Visit: Very much improved24
Last On-Treatment Visit: Much improved73
Last On-Treatment Visit: Minimally improved83
Last On-Treatment Visit: No change169
Last On-Treatment Visit: Minimally worse36
Last On-Treatment Visit: Much worse15
Last On-Treatment Visit: Very much worse1
SecondaryClinical Global Impression-Improvement in Participants, Subscale Motor Abilities: Assessment by Parent/Caregiver

The CGI-I scale is used to assess the severity of illness and global improvement in patients. Motor abilities function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of motor abilities was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

Time frame:
Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Reported as:
Count of participants · Participants
Clinical Global Impression-Improvement in Participants, Subscale Motor Abilities: Assessment by Parent/Caregiver
ParticipantsAny ZX008 Open Label Dose
Month 6: Very much improved17
Month 6: Much improved45
Month 6: Minimally improved86
Month 6: No change190
Month 6: Minimally worse26
Month 6: Much worse4
Month 6: Very much worse2
Month 12: Very much improved14
Month 12: Much improved31
Month 12: Minimally improved65
Month 12: No change134
Month 12: Minimally worse14
Month 12: Much worse6
Month 12: Very much worse1
Month 18: Very much improved10
Month 18: Much improved31
Month 18: Minimally improved48
Month 18: No change114
Month 18: Minimally worse16
Month 18: Much worse4
Month 18: Very much worse1
Month 24: Very much improved16
Month 24: Much improved19
Month 24: Minimally improved42
Month 24: No change97
Month 24: Minimally worse13
Month 24: Much worse1
Month 24: Very much worse0
Month 30: Very much improved7
Month 30: Much improved22
Month 30: Minimally improved27
Month 30: No change77
Month 30: Minimally worse13
Month 30: Much worse2
Month 30: Very much worse1
Month 36: Very much improved6
Month 36: Much improved16
Month 36: Minimally improved22
Month 36: No change67
Month 36: Minimally worse9
Month 36: Much worse7
Month 36: Very much worse1
Last On-Treatment Visit: Very much improved24
Last On-Treatment Visit: Much improved55
Last On-Treatment Visit: Minimally improved94
Last On-Treatment Visit: No change191
Last On-Treatment Visit: Minimally worse25
Last On-Treatment Visit: Much worse12
Last On-Treatment Visit: Very much worse0
SecondaryClinical Global Impression-Improvement in Participants, Subscale Cognition: Assessment by Investigator

The CGI-I scale is used to assess the severity of illness and global improvement in patients. Cognitive function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of cognition was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

Time frame:
Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Reported as:
Count of participants · Participants
Clinical Global Impression-Improvement in Participants, Subscale Cognition: Assessment by Investigator
ParticipantsAny ZX008 Open Label Dose
Month 6: Very much improved13
Month 6: Much improved54
Month 6: Minimally improved101
Month 6: No change184
Month 6: Minimally worse9
Month 6: Much worse2
Month 6: Very much worse2
Month 12: Very much improved13
Month 12: Much improved39
Month 12: Minimally improved79
Month 12: No change128
Month 12: Minimally worse4
Month 12: Much worse1
Month 12: Very much worse1
Month 18: Very much improved13
Month 18: Much improved32
Month 18: Minimally improved53
Month 18: No change118
Month 18: Minimally worse10
Month 18: Much worse0
Month 18: Very much worse0
Month 24: Very much improved9
Month 24: Much improved33
Month 24: Minimally improved55
Month 24: No change88
Month 24: Minimally worse3
Month 24: Much worse1
Month 24: Very much worse0
Month 30: Very much improved4
Month 30: Much improved25
Month 30: Minimally improved36
Month 30: No change81
Month 30: Minimally worse3
Month 30: Much worse0
Month 30: Very much worse0
Month 36: Very much improved4
Month 36: Much improved14
Month 36: Minimally improved34
Month 36: No change65
Month 36: Minimally worse7
Month 36: Much worse0
Month 36: Very much worse0
Last On-Treatment Visit: Very much improved16
Last On-Treatment Visit: Much improved64
Last On-Treatment Visit: Minimally improved103
Last On-Treatment Visit: No change201
Last On-Treatment Visit: Minimally worse12
Last On-Treatment Visit: Much worse1
Last On-Treatment Visit: Very much worse2
SecondaryClinical Global Impression-Improvement in Participants, Subscale Behavior: Assessment by Investigator

The CGI-I scale is used to assess the severity of illness and global improvement in patients. Behavior is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of behavior was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

Time frame:
Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Reported as:
Count of participants · Participants
Clinical Global Impression-Improvement in Participants, Subscale Behavior: Assessment by Investigator
ParticipantsAny ZX008 Open Label Dose
Month 6: Very much improved10
Month 6: Much improved42
Month 6: Minimally improved80
Month 6: No change200
Month 6: Minimally worse27
Month 6: Much worse5
Month 6: Very much worse1
Month 12: Very much improved11
Month 12: Much improved35
Month 12: Minimally improved54
Month 12: No change144
Month 12: Minimally worse17
Month 12: Much worse3
Month 12: Very much worse1
Month 18: Very much improved7
Month 18: Much improved32
Month 18: Minimally improved41
Month 18: No change122
Month 18: Minimally worse20
Month 18: Much worse3
Month 18: Very much worse1
Month 24: Very much improved11
Month 24: Much improved28
Month 24: Minimally improved36
Month 24: No change95
Month 24: Minimally worse17
Month 24: Much worse2
Month 24: Very much worse0
Month 30: Very much improved2
Month 30: Much improved28
Month 30: Minimally improved25
Month 30: No change77
Month 30: Minimally worse15
Month 30: Much worse2
Month 30: Very much worse0
Month 36: Very much improved1
Month 36: Much improved19
Month 36: Minimally improved28
Month 36: No change63
Month 36: Minimally worse11
Month 36: Much worse2
Month 36: Very much worse0
Last On-Treatment Visit: Very much improved14
Last On-Treatment Visit: Much improved57
Last On-Treatment Visit: Minimally improved74
Last On-Treatment Visit: No change229
Last On-Treatment Visit: Minimally worse20
Last On-Treatment Visit: Much worse3
Last On-Treatment Visit: Very much worse2
SecondaryClinical Global Impression Improvement in Participants, Subscale Motor Abilities: Assessment by Investigator

The CGI-I scale is used to assess the severity of illness and global improvement in patients. Motor abilities is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of motor abilities was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.

Time frame:
Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Reported as:
Count of participants · Participants
Clinical Global Impression Improvement in Participants, Subscale Motor Abilities: Assessment by Investigator
ParticipantsAny ZX008 Open Label Dose
Month 6: Very much improved10
Month 6: Much improved33
Month 6: Minimally improved81
Month 6: No change221
Month 6: Minimally worse17
Month 6: Much worse1
Month 6: Very much worse2
Month 12: Very much improved13
Month 12: Much improved29
Month 12: Minimally improved52
Month 12: No change159
Month 12: Minimally worse10
Month 12: Much worse0
Month 12: Very much worse2
Month 18: Very much improved9
Month 18: Much improved19
Month 18: Minimally improved42
Month 18: No change133
Month 18: Minimally worse21
Month 18: Much worse2
Month 18: Very much worse0
Month 24: Very much improved7
Month 24: Much improved24
Month 24: Minimally improved43
Month 24: No change99
Month 24: Minimally worse13
Month 24: Much worse3
Month 24: Very much worse0
Month 30: Very much improved4
Month 30: Much improved19
Month 30: Minimally improved29
Month 30: No change86
Month 30: Minimally worse9
Month 30: Much worse1
Month 30: Very much worse1
Month 36: Very much improved2
Month 36: Much improved9
Month 36: Minimally improved27
Month 36: No change74
Month 36: Minimally worse8
Month 36: Much worse4
Month 36: Very much worse0
Last On-Treatment Visit: Very much improved12
Last On-Treatment Visit: Much improved39
Last On-Treatment Visit: Minimally improved89
Last On-Treatment Visit: No change238
Last On-Treatment Visit: Minimally worse16
Last On-Treatment Visit: Much worse4
Last On-Treatment Visit: Very much worse1
SecondaryNumber of Participants With Improvement in Seizure Burden as Assessed by the Investigator

The change in seizure burden from the previous visit was assessed by the investigator using following categories: \<25%, ≥25%, ≥50%, ≥75%, 100% (i.e., seizure-free) improvement. Improvement in seizure burden at Baseline was based on comparison with the participant's last visit in the feeder studies (ZX008-1601, ZX008-1503, and ZX008-1602). Number of participants in each of the 5 categories is reported for each visit as compared to last visit.

Time frame:
Baseline (Day 1), Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Reported as:
Count of participants · Participants
Number of Participants With Improvement in Seizure Burden as Assessed by the Investigator
ParticipantsAny ZX008 Open Label Dose
Baseline: <25%242
Baseline: >=25%67
Baseline: >=50%42
Baseline: >=75%35
Baseline: 100%12
Month 6: <25%262
Month 6: >=25%51
Month 6: >=50%39
Month 6: >=75%21
Month 6: 100%8
Month 12: <25%191
Month 12: >=25%33
Month 12: >=50%31
Month 12: >=75%11
Month 12: 100%6
Month 18: <25%175
Month 18: >=25%22
Month 18: >=50%26
Month 18: >=75%3
Month 18: 100%6
Month 24: <25%144
Month 24: >=25%24
Month 24: >=50%15
Month 24: >=75%6
Month 24: 100%4
Month 30: <25%115
Month 30: >=25%14
Month 30: >=50%11
Month 30: >=75%7
Month 30: 100%1
Month 36: <25%99
Month 36: >=25%13
Month 36: >=50%9
Month 36: >=75%6
Month 36: 100%1
Last On-Treatment Visit: <25%315
Last On-Treatment Visit: >=25%41
Last On-Treatment Visit: >=50%29
Last On-Treatment Visit: >=75%17
Last On-Treatment Visit: 100%8

Adverse events

Collected over From First dose of ZX008 (in study EP0215 [ZX008-1900]) to Cardiac Follow-up after ZX008 treatment (Up to 6 Years, 17 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Any ZX008 Open Label Dose3/412 (0.7%)67/412 (16.3%)204/412 (49.5%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventAny ZX008 Open Label Dose
SeizureNervous system disorders17/412
Status epilepticusNervous system disorders9/412
PneumoniaInfections and infestations8/412
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders5/412
DehydrationMetabolism and nutrition disorders3/412
AstheniaGeneral disorders2/412
AppendicitisInfections and infestations2/412
Corona virus infectionInfections and infestations2/412
Pneumonia viralInfections and infestations2/412
Urinary tract infectionInfections and infestations2/412
Most frequent other events
Most frequent other events
EventAny ZX008 Open Label Dose
Corona virus infectionInfections and infestations84/412
PyrexiaGeneral disorders53/412
SeizureNervous system disorders52/412
NasopharyngitisInfections and infestations49/412
DiarrhoeaGastrointestinal disorders29/412
Decreased appetiteMetabolism and nutrition disorders25/412
Upper respiratory tract infectionInfections and infestations23/412

Baseline characteristics

Baseline Characteristics refer to the Safety analysis set which consisted of all participants who received at least one dose of ZX008 during the open label extension (OLE).

Age, Continuous
Age, Continuous(Years)Any ZX008 Open Label Dose
Mean14.1 ± 6.8
Age, Customized
Age, Customized(Participants)Any ZX008 Open Label Dose
2 - <12 years168
12 - <18 years117
18 - <65 years127
Sex: Female, Male
Sex: Female, Male(Participants)Any ZX008 Open Label Dose
Female191
Male221
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Any ZX008 Open Label Dose
American Indian or Alaska Native4
Asian19
Black or African American11
Native Hawaiian or Other Pacific Islander1
White327
Other or Mixed4
Not Reported35
Unknown11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Any ZX008 Open Label Dose
Hispanic or Latino60
Not Hispanic or Latino303
Not Reported42
Unknown7
08

Study locations

71 sites
  • Ep0215 107
    Tucson, Arizona 85718, United States
  • Ep0215 144
    Los Angeles, California 90095, United States
  • Ep0215 108
    San Diego, California 92123, United States
  • Ep0215 101
    San Francisco, California 94158, United States
  • Ep0215 103
    Aurora, Colorado 80045, United States
  • Ep0215 115
    Gulf Breeze, Florida 32561, United States
  • Ep0215 104
    Miami, Florida 33155, United States
  • Ep0215 141
    Orlando, Florida 32803, United States
  • Ep0215 121
    Winter Park, Florida 32789, United States
  • Ep0215 117
    Atlanta, Georgia 30328, United States
  • Ep0215 110
    Chicago, Illinois 60611-2605, United States
  • Ep0215 140
    Bethesda, Maryland 20817, United States
  • Ep0215 112
    Boston, Massachusetts 02114, United States
  • Ep0215 109
    Rochester, Minnesota 55905, United States
  • Ep0215 132
    Roseville, Minnesota 55113, United States
  • Ep0215 105
    Hackensack, New Jersey 07601, United States
  • Ep0215 118
    Livingston, New Jersey 07039, United States
  • Ep0215 150
    Hawthorne, New York 10532, United States
  • Ep0215 142
    New York, New York 10016, United States
  • Ep0215 131
    Cleveland, Ohio 44106, United States
  • Ep0215 124
    Memphis, Tennessee 38103, United States
  • Ep0215 146
    Dallas, Texas 75207, United States
  • Ep0215 126
    Fort Worth, Texas 76104, United States
  • Ep0215 106
    Salt Lake City, Utah 84108, United States
  • Ep0215 119
    Seattle, Washington 98105, United States
  • Ep0215 125
    Tacoma, Washington 98405, United States
  • Ep0215 301
    Heidelberg, Australia
  • Ep0215 302
    South Brisbane, Australia
  • Ep0215 303
    Westmead, Australia
  • Ep0215 803
    Brussels, Belgium
  • Ep0215 801
    Edegem, Belgium
  • Ep0215 802
    Jette, Belgium
  • Ep0215 202
    Montreal, Canada
  • Ep0215 204
    Toronto, Canada
  • Ep0215 201
    Vancouver, Canada
  • Ep0215 701
    Dianalund, Denmark
  • Ep0215 1004
    Bordeaux, France
  • Ep0215 1005
    Lille, France
  • Ep0215 1007
    Marseille, France
  • Ep0215 1001
    Paris, France
  • Ep0215 1002
    Paris, France
  • Ep0215 1008
    Salouël, France
  • Ep0215 902
    Bielefeld, Germany
  • Ep0215 906
    Freiburg im Breisgau, Germany
  • Ep0215 905
    Jena, Germany
  • Ep0215 908
    Kiel, Germany
  • Ep0215 903
    Radeberg, Germany
  • Ep0215 901
    Vogtareuth, Germany
  • Ep0215 1201
    Florence, Italy
  • Ep0215 1204
    Genova, Italy
  • Ep0215 1205
    Mantua, Italy
  • Ep0215 1207
    Milan, Italy
  • Ep0215 1206
    Roma, Italy
  • Ep0215 1208
    Roma, Italy
  • Ep0215 1202
    Verona, Italy
  • Ep0215 1604
    Guadalajara, Mexico
  • Ep0215 1402
    Heeze, Netherlands
  • Ep0215 1401
    Zwolle, Netherlands
  • Ep0215 1702
    Bydgoszcz, Poland
  • Ep0215 1701
    Krakow, Poland
  • Ep0215 1105
    Barcelona, Spain
  • Ep0215 1107
    Barcelona, Spain
  • Ep0215 1103
    Esplugues de Llobregat, Spain
  • Ep0215 1101
    Madrid, Spain
  • Ep0215 1102
    Pamplona, Spain
  • Ep0215 502
    Gothenburg, Sweden
  • Ep0215 605
    Birmingham, United Kingdom
  • Ep0215 601
    Glasgow, United Kingdom
  • Ep0215 603
    Liverpool, United Kingdom
  • Ep0215 602
    London, United Kingdom
  • Ep0215 606
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in May 2025, 72 months.

Results were first posted in Nov 2025, 6 months after primary completion.

Of 15 phase 3 interventional studies under Epilepsies, Myoclonic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 72. This study's 72 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2019
First posted
May 3, 2019
StartActual
Apr 22, 2019
Primary completionActual
May 8, 2025
CompletionActual
May 8, 2025
Results first posted
Nov 17, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03936777
Lead sponsor
Zogenix, Inc.
Responsible party
Sponsor
First posted
May 3, 2019
Start date
Apr 22, 2019
Primary completion
May 8, 2025
Completion
May 8, 2025
Results posted
Nov 17, 2025
Last update
Nov 17, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenfluramine

Start the discussion